BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed OMER catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:4ec1ac26d3f1ec3c96f1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:OMER P2 readout (est.): Long-Term Safety\, Tolerability and Efficac
 y of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
DESCRIPTION:Long-Term Safety\, Tolerability and Efficacy of OMS906 in Parox
 ysmal Nocturnal Hemoglobinuria\nNCT06298955 | PHASE2 | ACTIVE_NOT_RECRUITI
 NG | sponsor: Omeros Corporation\nPrimary completion date (ESTIMATED)\; to
 p-line results usually follow later.\nDate precision: month (shown on the 
 first day)\nTicker OMER (confidence 0.9)\nSource: https://clinicaltrials.g
 ov/study/NCT06298955\nScheduling/reference data from public records\; date
 s can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06298955
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:07b493e0221f209ecc69@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251223
DTEND;VALUE=DATE:20251224
SUMMARY:OMER APPROVAL: YARTEMLEA
DESCRIPTION:Approved 2025-12-23: YARTEMLEA (BLA761152 ORIG1)\nConfidence: c
 onfirmed\nTicker OMER (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761152\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761152
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
